Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma

Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities

(2020) Johannes Gojo et al.   Frontiers in Oncology

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

(2020) Young K. Chae et al.   JOURNAL OF CLINICAL ONCOLOGY

A cell-based MAPK reporter assay reveals synergistic MAPK pathway activity suppression by MAPK inhibitor combination in BRAF-driven pediatric low-grade glioma cells

(2020) Diren Usta et al.   MOLECULAR CANCER THERAPEUTICS

Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein

(2020) Holger Fischer et al.   NEURO-ONCOLOGY

Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification

(2020) Dirk Hempel et al.   ONCOLOGIST

Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes

(2020) Matthew Clarke et al.   Cancer Discovery

The limitations of targeting MEK signalling in Glioblastoma therapy

(2020) Karthika D. Selvasaravanan et al.   Scientific Reports

Treatment of Advanced/Metastatic Melanoma in the United States and Western Europe: Results of the CancerMPact Survey

(2020) Stephanie Hawthorne et al.   Cancer Management and Research

Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients

(2020) Armin Sebastian Guntner et al.   Acta Neuropathologica Communications

Molecular and clinicopathologic features of gliomas harboring NTRK fusions

(2020) Matthew Torre et al.   Acta Neuropathologica Communications

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

(2020) Reinhard Dummer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Larotrectinib in adult patients with solid tumours: a multicentre, open-label, phase I dose-escalation study

(2019) D S Hong et al.   ANNALS OF ONCOLOGY

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma

(2019) Cyril Neftel et al.   CELL

Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience

(2019) Elke Pfaff et al.   EUROPEAN JOURNAL OF CANCER

Resistance to TRK inhibition mediated by convergent MAPK pathway activation

(2019) Emiliano Cocco et al.   NATURE MEDICINE

Larotrectinib imaging response in low‐grade glioma

(2019) Andrew W. Walter et al.   PEDIATRIC BLOOD & CANCER

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma

(2019) Lisa Gabler et al.   Acta Neuropathologica Communications

Efficacy and safety of dabrafenib–trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF‐V600 mutation: A systematic review and network meta‐analysis

(2019) Nathaly Garzón‐Orjuela et al.   Dermatologic Therapy

Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas

(2019) Ana S. Guerreiro Stucklin et al.   Nature Communications

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing

(2019) Kazuko Sakai et al.   Scientific Reports

TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

(2019) Ezra Y Rosen et al.   CLINICAL CANCER RESEARCH

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

(2019) Robert C Doebele et al.   LANCET ONCOLOGY

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies

(2018) Priscilla K. Brastianos et al.   ONCOLOGIST

Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma

(2018) David S. Ziegler et al.   BRITISH JOURNAL OF CANCER

NTRK fusion-positive cancers and TRK inhibitor therapy

(2018) Emiliano Cocco et al.   Nature Reviews Clinical Oncology

P14.19 Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions

(2017) S. Rangaraju et al.   NEURO-ONCOLOGY

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

(2017) Alexander Drilon et al.   Cancer Discovery

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

(2017) Alexander Drilon et al.   Cancer Discovery

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

What hides behind the MASC: clinical response and acquired resistance to entrectinib afterETV6-NTRK3identification in a mammary analogue secretory carcinoma (MASC)

(2016) A. Drilon et al.   ANNALS OF ONCOLOGY

Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors

(2016) Kristian W. Pajtler et al.   JOURNAL OF NEURO-ONCOLOGY

Secretory Breast Carcinoma

(2015) Marie Del Castillo et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

(2015) Anna F. Farago et al.   Journal of Thoracic Oncology

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer

(2015) M. Russo et al.   Cancer Discovery

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

(2014) A. W. Tolcher et al.   ANNALS OF ONCOLOGY

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

(2014) A. P. Patel et al.   SCIENCE

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

(2012) T. Shimizu et al.   CLINICAL CANCER RESEARCH

Survey of 548 oncogenic fusion transcripts in thyroid tumors supports the importance of the already established thyroid fusions genes

(2012) Ricardo Celestino et al.   GENES CHROMOSOMES & CANCER

Advanced Stage, Increased Lactate Dehydrogenase, and Primary Site, but Not Adolescent Age (≥ 15 Years), Are Associated With an Increased Risk of Treatment Failure in Children and Adolescents With Mature B-Cell Non-Hodgkin's Lymphoma: Results of the FAB LMB 96 Study

(2012) Mitchell S. Cairo et al.   JOURNAL OF CLINICAL ONCOLOGY

A restricted cell population propagates glioblastoma growth after chemotherapy

(2012) Jian Chen et al.   NATURE

Paediatric and adult malignant glioma: close relatives or distant cousins?

(2012) Chris Jones et al.   Nature Reviews Clinical Oncology

Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: A Children's Oncology Group trial (P9962)

(2011) Samara L. Poplack Potter et al.   PEDIATRIC BLOOD & CANCER

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma

(2010) Lucie Lafay-Cousin et al.   Journal of Neurosurgery-Pediatrics

Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: Results of the first UKCCSG/SIOP CNS 9204 trial

(2009) R.G. Grundy et al.   EUROPEAN JOURNAL OF CANCER